Articles tagged with Human Immunodeficiency Virus
Scientists have created a substance that targets amyloid structures in semen and weakens HIV's ability to infect the body's immune cells. The experimental compound makes it harder for HIV particles to stick to human immune cells, offering a new lead in developing a microbicide to prevent HIV transmission.
Researchers have successfully slipped silver nanoparticles cloaked in HIV protein into the nucleus of cells, where they can detect subtle light signals and deliver payloads. This innovation has potential implications for disease treatment and basic scientific research.
A Stanford study finds that 90% of emergency departments nationwide provide preventive-care services, despite being under pressure to prioritize acute care. The most common service is domestic violence screening, while HIV screening is the least offered. Many EDs struggle to balance quality and cost constraints.
Researchers have developed a method to extract and present viral surface fragments, known as epitopes, into computer-designed protein scaffolds that lock them in recognizable shapes. This approach has implications for vaccine design and the development of antibodies against HIV/AIDS.
Researchers have discovered that a precursor to the AIDS-causing HIV is at least 32,000 years old, contradicting previous estimates. The study suggests that HIV's evolution into a non-lethal form is unlikely due to its rapid virulence.
Scientists have discovered that Simian Immunodeficiency Virus (SIV), an ancestor of HIV, is thousands of years old, challenging previous estimates. The research suggests SIV may be even older than a million years and has implications for understanding the origin of HIV.
Drs. De Clercq and Fauci are recognized for their pioneering work in understanding and combating HIV/AIDS. They have made significant contributions to the development of antiviral drugs and treatments.
Researchers found a sensor in dendritic cells that recognizes HIV, sparking a more potent immune response. The ability to stimulate this protective response is critical for developing therapeutic vaccines against HIV.
Researchers found that villagers with higher cognitive and decision-making abilities were more likely to take protective steps against HIV. Formal education was key to teaching people how to think critically and make informed decisions.
In France, nearly half of new HIV infections occur among men who have sex with men, accounting for 48% of new cases in 2008. Incidence is 200 times higher than in the French heterosexual population.
Research found that young white homosexual men contribute significantly to local HIV spread, highlighting high-risk behavior as a major factor. The study's findings suggest targeted prevention programs focused on this group are needed to combat rising infections.
Scientists have identified six critical amino acids in the TRIM5α protein that enable it to destroy HIV. Altering these amino acids in human cells renders TRIM5α ineffective against HIV-1 infection, highlighting a potential target for therapy development.
A new HIV drug candidate called PIE12-trimer has been developed by a University of Utah biochemist, which prevents the virus from attacking human cells. The compound is designed with a unique resistance capacitor that makes it effective against emerging drug-resistant viruses.
A joint project of UCSF and KEMRI has received a 5-year grant to expand its care and support for people affected by HIV/AIDS in Kenya. The grant will allow the project to serve at least 80% of HIV patients needing care within its service areas.
A work group led by a Kaiser Permanente researcher developed and adopted 17 national measures to assess HIV care quality, including screening, prevention, and antiretroviral therapy. These measures have been endorsed by several organizations and are being pilot-tested to improve patient outcomes.
The Robert Wood Johnson Foundation recognizes 10 Community Health Leaders who have improved the lives of men, women, and children in underserved communities. The awardees receive $125,000 to support their ongoing work.
Catherine A. Blish receives ICAAC Young Investigator Award for elucidating neutralizing antibodies in HIV transmission, sponsored by Merck. Her work shows that broad neutralizing antibody responses may not prevent superinfection with a second strain of HIV.
A US-Mexico border program using a 35-minute behavioral intervention significantly reduced the incidence of HIV and STIs among female sex workers. The program, called Mujer Segura or Healthy Woman, was found to be cost-effective, with an estimated expense per intervention of less than $200.
The PLOS Medicine editors argue for a more integrated approach to addressing HIV in maternal and child health. Concurrent crises of maternal and child health and HIV require cooperation to address effectively.
A five-year, $4 million NIH grant will support a prospective study on antiretroviral therapy for people co-infected with MDR-TB and HIV in South Africa. The study aims to gather evidence for clinical practice and public health policy worldwide.
The XVIII International AIDS Conference presented strong scientific findings on HIV research and program scale-up, emphasizing the need for increased funding and human rights protection. Delegates renewed their commitment to securing universal access to prevention, care, treatment, and support.
The mother-to-child HIV transmission rate has dropped significantly since the advent of powerful therapies, with fewer than 10 babies born with the disease annually in Florida. Despite progress, there are still missed opportunities for prevention, particularly among women with mental health issues or substance abuse problems.
A new study suggests that adult circumcision would have a very small effect on reducing HIV incidence in the US. The study found that only 500 out of 65,700 gay and bisexual men in San Francisco would potentially benefit from circumcision.
The lack of access to scientifically proven interventions for key populations at risk and the lagging scale-up of treatment regimens threaten future progress on AIDS. Organizers call for an end to passive neglect and active denial of life-saving health services, information, and tools.
The Lancet series on HIV in people who use drugs highlights the need to shift focus from individual patient adherence to health delivery conditions that create treatment interruptions. The series reports that increased ART provision to IDUs reduces infectivity and transmission, and is cost-effective.
Less than 1 in 10 injecting drug users globally are covered by effective HIV prevention interventions, with most relying on a combination of needle and syringe programs, opioid substitution therapy, and antiretroviral therapy. Scaling up these combined approaches is crucial to reduce HIV transmission among IDUs.
HIV-infected drug users are at a higher risk of developing co-morbidities such as viral hepatitis, tuberculosis, and mental illness. Evidence-based treatments like medication-assisted therapies can improve treatment outcomes and reduce mortality rates.
Dr. Fauci presents new insights on the early pathogenic events following sexual exposure to HIV, informing strategies for prevention and vaccination. He focuses on the role of α4β7 in enhancing HIV binding to CD4+ T cells, a potential target for vaccine development.
The growing HIV epidemic in people who use drugs is a significant public health concern, with 16 million injecting drug users worldwide and 3 million living with HIV. A comprehensive approach combining access to antiretroviral treatment, opioid substitution therapy, and needle programs can help contain the outbreak.
Experts conclude that inadequate provision of opioid substitution therapy, needle exchange programs, and antiretroviral treatment, along with laws prohibiting OST, are all contributing to the spread of HIV among people who use drugs. Scaling up combination HIV prevention interventions is shown to be effective in curbing the epidemic.
The large-scale roll-out of adult male circumcision (AMC) in Orange Farm, South Africa has been successful in reducing HIV prevalence. The study's findings suggest that AMC can be a feasible short-term strategy for HIV prevention in low-income communities with high HIV prevalence.
Children account for 18% of HIV-related deaths and 15% of infections annually, highlighting the need for improved testing. New approaches, such as routine newborn testing, could help detect more children with HIV in resource-limited settings.
Injecting drug users can achieve excellent virological outcomes with ART, reducing infectivity and HIV transmission. Decriminalization and law reform are crucial to overcome systemic barriers and promote equitable access to treatment.
Experts call for decriminalization of drug users, alongside a massive scale-up of opioid substitution, needle and syringe programs, and antiretroviral treatment. Current treatment programmes only reach around 10% of people who use drugs worldwide, highlighting the need for reform in justice systems and policy decision making.
A meta-analysis found that only intensive, multi-session treatment programs reduced amphetamine use. The authors emphasize the need for scalable and cost-effective interventions to address the relationship between amphetamine drug use and HIV risk.
A UBC-BC CfE study found that increased HAART coverage significantly prevents HIV transmission and reduces new diagnoses in British Columbia. The expansion of HAART treatment plays a crucial role in maximizing public health resources.
The new guidelines recommend initiating antiretroviral treatment (ART) as soon as possible for asymptomatic individuals with low CD4+ cell counts, and treating symptomatic patients regardless of their CD4+ count. The treatment should be individualized based on concurrent conditions and previous drug exposure.
A study found that only 51% of HIV-exposed infants in African countries received a minimum dose of nevirapine to reduce the risk of mother-to-child transmission. The study highlights the need for improved service coverage and counseling services to maximize prevention efforts.
A Canadian study found that the introduction of highly active antiretroviral therapy (HAART) for HIV patients in 1996 led to a significant decrease in new HIV diagnoses. The study showed that every 100 patients on HAART resulted in a 3% reduction in new HIV diagnoses.
A study found that routine HIV screenings in emergency departments resulted in a small increase in newly diagnosed HIV patients, with most diagnoses occurring late in the course of disease. The findings suggest that nontargeted opt-out rapid HIV screening may be an effective prevention strategy.
A recent NIH-supported study found that increasing HAART coverage in British Columbia reduced viral load and new HIV diagnoses among individuals with a history of injection drug use. The study's findings support the importance of maximizing HAART coverage within current medical guidelines to curb the spread of HIV.
The International AIDS Society (IAS) has announced the winners of four prestigious scientific awards, recognizing innovative HIV and AIDS research. The Women, Girls and HIV Investigator Prize was awarded to Naina Rani for her work on mainstreaming the Prevention of Parent to Child Transmission program in India.
Penn State researchers discovered that retroviruses like HIV take a detour through the cell nucleus before assembling new virus particles. Understanding this process could enable the development of drugs to stop the spread of infection.
Researchers developed two new risk models to predict the survival of HIV patients in sub-Saharan Africa. The models identified key factors such as CD4 cell count, clinical stage, and bodyweight that increase the risk of death. These predictions will aid in clinical decision making and improve treatment outcomes.
A new study found that HIV may increase the risk of death in people with high CD4 counts, but only moderately. The risk was highest among injecting drug users and heterosexual individuals, likely due to socioeconomic factors rather than HIV itself.
The International AIDS Society has awarded $3.4 million in grants to 10 early-stage researchers from diverse scientific disciplines, aiming to advance HIV understanding and prevention approaches. The grantees will collaborate with CFAR institutions to explore pressing scientific questions on long-term survival and HIV transmission.
A new review of existing literature found that several factors influence willingness to receive an HIV vaccine, including misconceptions about vaccine efficacy and fear of side effects. To ensure a future HIV vaccine is acceptable, public education is crucial to address these concerns.
The report identifies key gaps in current knowledge and proposes a multi-disciplinary research approach to support HIV-positive women's reproductive health. The recommendations aim to enhance their ability to achieve their desired family size and promote healthy services.
A study of gay male couples found that sexual agreements mainly improve relationship satisfaction and build trust. However, broken agreements can increase HIV risk when partners have different understandings of their agreement.
Three former Latin American presidents have signed the Vienna Declaration, calling for the incorporation of scientific evidence into illicit drug policies. The declaration aims to improve community health and safety by reducing consumption and harm caused by drugs.
A new study found that a culturally specific intervention program based on the African concept of Eban increased condom use and reduced acts of unprotected sex among heterosexual African American couples with differing HIV status. The program aimed to improve communication, relationship health, and community respect.
A couple-focused intervention appears effective in reducing HIV risk behaviors among African-American couples, particularly those with one partner HIV-positive. The study found that couples who participated in the Eban intervention reported more consistent condom use and fewer unprotected intercourse acts.
The International AIDS Society and National Institute on Drug Abuse have awarded fellowships to seven young researchers from around the world to study the intersection of drug use and HIV. The recipients will receive US$75,000 each to pursue groundbreaking research in biology, epidemiology, public health, behavioral sciences, and more.
Experts warn that failure to meet universal access pledge and budget cuts to prevention and treatment programs will deliver a major setback. Many African countries face depleting stocks of antiretroviral medications and reduced treatment coverage goals, increasing the risk of HIV drug resistance.
Researchers have found two human antibodies, VRC01 and VRC02, that can neutralize over 90% of known HIV strains. These antibodies could be used to design improved HIV vaccines or developed as a therapy for HIV infection. The discovery was made using a novel molecular device that targets specific cells making antibodies against HIV.
Increasing HAART treatment for people with HIV/AIDS lowers viral load, stops HIV progression, and prevents transmission. A comprehensive economic analysis shows expanding HAART coverage in British Columbia can deliver a net benefit of $900 million over 30 years.
A recent study published in PLoS Pathogens has identified two molecules, PPARγ and LXR, that can inhibit specific aspects of HIV transmission. The findings suggest that these molecules may be targets for therapies targeting mucosal HIV transmission.
A recent study found that the original HIV strain still exists in the body months after initial infection, with immune cells degrading it at an accelerated rate. The research analyzed over 100,000 genetic snippets and revealed that the virus mutates rapidly to evade the immune system, but certain portions remain persistent.
The Vienna Declaration urges governments and international organizations to adopt evidence-based approaches to illicit drug policy, recognizing addiction as a medical condition. This declaration aims to reduce harms deriving from current policies and redirect resources towards prevention, treatment, and harm reduction interventions.
A new report confirms that routine, jail-based HIV testing can identify a substantial proportion of people unknowingly infected with HIV. The study found nearly 170 new HIV diagnoses among Rhode Island inmates during an eight-year period, highlighting the potential for this testing to prevent disease spread.